carbamates has been researched along with Renal Insufficiency, Chronic in 32 studies
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min." | 8.12 | Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). ( Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S, 2022) |
| "Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited." | 8.12 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. ( Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS, 2022) |
| "In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5 chronic kidney disease resulted in a high rate of virological cure compared with placebo." | 5.24 | Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial ( Arduino, JM; Barr, E; Bruchfeld, A; Greaves, W; Hwang, P; Londoño, MC; Martin, P; Monsour, H; Nelson, DR; Nguyen, BY; Pol, S; Robertson, M; Roth, D; Silva, M; Wahl, J, 2017) |
| "Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min." | 4.12 | Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). ( Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S, 2022) |
| "Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited." | 4.12 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. ( Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS, 2022) |
| "Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infected patients with or without compensated liver cirrhosis." | 3.96 | Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. ( Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Blaszkowska, M; Buczyńska, I; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D, 2020) |
| "We conducted an observational prospective study, on 232 patients with chronic kidney disease, undergoing treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir, for chronic hepatitis C infection - genotype 1b." | 3.96 | Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. ( Iliescu, EL; Mercan-Stanciu, A; Toma, L, 2020) |
| "The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin." | 3.91 | Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort. ( Dabes, H; ElSaeed, K; ElSerafy, M; ElShazly, Y; Hamed, S; Omar, H; Saad, Y; Said, M; Soliman, Z, 2019) |
| " The most common adverse event was anemia, which was more common in group 2." | 1.91 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease. ( Ammar, I; Doss, W; El Raziky, M; El-Sayed, M; Elakel, W; Elsaeed, K; Elserafy, M; Elshazly, Y; Fayad, T; Hassany, M; Korany, M; Mahrous, M; Mehrez, M; Saad, Y; Salama, R; Zaki, A, 2023) |
| "7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision." | 1.51 | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. ( Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019) |
| "In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs)." | 1.51 | Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. ( Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J, 2019) |
| " RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily." | 1.48 | High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. ( Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018) |
| "Homocitrulline (HCit) is a carbamylation-derived product (CDP) that has been identified as a valuable biomarker of morbidity and mortality in patients with chronic kidney disease (CKD)." | 1.43 | Homocitrulline as marker of protein carbamylation in hemodialyzed patients. ( Desmons, A; Fadel, F; Gillery, P; Jaisson, S; Kazes, I; Millart, H; Oudart, JB; Rieu, P; Santos-Weiss, IC; Touré, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (75.00) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sayed, M | 1 |
| Elserafy, M | 2 |
| El Raziky, M | 1 |
| Elakel, W | 1 |
| Saad, Y | 2 |
| Fayad, T | 1 |
| Korany, M | 1 |
| Mehrez, M | 1 |
| Salama, R | 1 |
| Mahrous, M | 1 |
| Zaki, A | 1 |
| Hassany, M | 1 |
| Ammar, I | 1 |
| Elsaeed, K | 2 |
| Elshazly, Y | 2 |
| Doss, W | 1 |
| Londoño, MC | 4 |
| Riveiro-Barciela, M | 1 |
| Ahumada, A | 1 |
| Muñoz-Gómez, R | 1 |
| Roget, M | 1 |
| Devesa-Medina, MJ | 1 |
| Serra, MÁ | 1 |
| Navascués, CA | 1 |
| Baliellas, C | 1 |
| Aldamiz-Echevarría, T | 1 |
| Gutiérrez, ML | 1 |
| Polo-Lorduy, B | 1 |
| Carmona, I | 1 |
| Benlloch, S | 1 |
| Bonet, L | 1 |
| García-Samaniego, J | 1 |
| Jiménez-Pérez, M | 1 |
| Morán-Sánchez, S | 1 |
| Castro, Á | 1 |
| Delgado, M | 1 |
| Gea-Rodríguez, F | 1 |
| Martín-Granizo, I | 1 |
| Montes, ML | 1 |
| Morano, L | 1 |
| Castaño, MA | 1 |
| de Los Santos, I | 1 |
| Laguno, M | 2 |
| Losa, JE | 1 |
| Montero-Alonso, M | 1 |
| Rivero, A | 1 |
| de Álvaro, C | 1 |
| Manzanares, A | 1 |
| Mallolas, J | 2 |
| Barril, G | 1 |
| González-Parra, E | 1 |
| García-Buey, L | 1 |
| Wiegand, J | 2 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 2 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 2 |
| Manns, MP | 1 |
| Zeuzem, S | 2 |
| Berg, T | 2 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Zarębska-Michaluk, D | 1 |
| Jaroszewicz, J | 1 |
| Buczyńska, I | 1 |
| Simon, K | 1 |
| Lorenc, B | 1 |
| Tudrujek-Zdunek, M | 1 |
| Tomasiewicz, K | 1 |
| Sitko, M | 1 |
| Garlicki, A | 1 |
| Janczewska, E | 1 |
| Dybowska, D | 1 |
| Halota, W | 1 |
| Pawłowska, M | 1 |
| Pabjan, P | 1 |
| Mazur, W | 1 |
| Czauż-Andrzejuk, A | 1 |
| Berak, H | 1 |
| Horban, A | 1 |
| Socha, Ł | 1 |
| Klapaczyński, J | 1 |
| Piekarska, A | 1 |
| Blaszkowska, M | 1 |
| Belica-Wdowik, T | 1 |
| Dobracka, B | 1 |
| Tronina, O | 1 |
| Deroń, Z | 1 |
| Białkowska-Warzecha, J | 1 |
| Laurans, Ł | 1 |
| Flisiak, R | 1 |
| Choi, DT | 1 |
| Puenpatom, A | 1 |
| Yu, X | 1 |
| Erickson, KF | 1 |
| Kanwal, F | 1 |
| El-Serag, HB | 1 |
| Kramer, JR | 1 |
| Iliescu, EL | 1 |
| Mercan-Stanciu, A | 1 |
| Toma, L | 1 |
| Huang, CF | 1 |
| Yu, ML | 1 |
| Stein, K | 1 |
| Stoehr, A | 1 |
| Teuber, G | 1 |
| Naumann, U | 1 |
| John, C | 1 |
| Heyne, R | 1 |
| Niederau, C | 1 |
| Li, C | 1 |
| Liang, J | 1 |
| Xiang, H | 1 |
| Chen, H | 1 |
| Tian, J | 1 |
| Liu, CH | 1 |
| Chen, CY | 1 |
| Su, WW | 1 |
| Tseng, KC | 1 |
| Lo, CC | 1 |
| Liu, CJ | 1 |
| Chen, JJ | 1 |
| Peng, CY | 1 |
| Shih, YL | 1 |
| Yang, SS | 1 |
| Huang, CS | 1 |
| Huang, KJ | 1 |
| Chang, CY | 1 |
| Tsai, MC | 1 |
| Kao, WY | 1 |
| Fang, YJ | 1 |
| Chen, PY | 1 |
| Su, PY | 1 |
| Tseng, CW | 1 |
| Huang, JJ | 1 |
| Lee, PL | 1 |
| Lai, HC | 1 |
| Hsieh, TY | 1 |
| Chang, CH | 1 |
| Huang, YJ | 1 |
| Lee, FJ | 1 |
| Chang, CC | 1 |
| Kao, JH | 1 |
| Delanghe, S | 1 |
| Moerman, A | 1 |
| Pletinck, A | 1 |
| Schepers, E | 1 |
| Glorieux, G | 1 |
| Van Biesen, W | 1 |
| Delanghe, JR | 1 |
| Speeckaert, MM | 1 |
| Bruchfeld, A | 2 |
| Roth, D | 3 |
| Martin, P | 3 |
| Nelson, DR | 2 |
| Pol, S | 2 |
| Monsour, H | 2 |
| Silva, M | 2 |
| Hwang, P | 1 |
| Arduino, JM | 1 |
| Robertson, M | 2 |
| Nguyen, BY | 2 |
| Wahl, J | 2 |
| Barr, E | 2 |
| Greaves, W | 3 |
| Morisawa, N | 2 |
| Koshima, Y | 2 |
| Kuriyama, S | 2 |
| Matsuyama, M | 1 |
| Hayashi, N | 1 |
| Satoh, JI | 2 |
| Amemiya, M | 2 |
| Yokoo, T | 2 |
| Nicolas, C | 1 |
| Jaisson, S | 3 |
| Gorisse, L | 2 |
| Tessier, FJ | 1 |
| Niquet-Léridon, C | 1 |
| Jacolot, P | 1 |
| Pietrement, C | 2 |
| Gillery, P | 3 |
| Sanai, FM | 1 |
| Alghamdi, AS | 1 |
| Afghani, AA | 1 |
| Alswat, K | 1 |
| AlZanbagi, A | 1 |
| Alghamdi, MN | 1 |
| AlMousa, A | 1 |
| Aseeri, M | 1 |
| Assiri, AM | 1 |
| Babatin, MA | 1 |
| Goel, A | 1 |
| Bhadauria, DS | 1 |
| Kaul, A | 1 |
| Verma, P | 1 |
| Mehrotra, M | 1 |
| Gupta, A | 1 |
| Sharma, RK | 1 |
| Rai, P | 1 |
| Aggarwal, R | 1 |
| Nayak, SL | 1 |
| Gupta, E | 1 |
| Kataria, A | 1 |
| Sarin, SK | 1 |
| Abdel-Razek, W | 1 |
| Waked, I | 1 |
| Maduell, F | 1 |
| Belmar, L | 1 |
| Ugalde, J | 1 |
| Martínez-Rebollar, M | 1 |
| Ojeda, R | 1 |
| Arias, M | 1 |
| Rodas, L | 1 |
| Rossi, F | 1 |
| Llovet, LP | 1 |
| González, LN | 1 |
| Ogawa, E | 1 |
| Furusyo, N | 1 |
| Azuma, K | 1 |
| Nakamuta, M | 1 |
| Nomura, H | 1 |
| Dohmen, K | 1 |
| Satoh, T | 1 |
| Kawano, A | 1 |
| Koyanagi, T | 1 |
| Ooho, A | 1 |
| Takahashi, K | 1 |
| Kato, M | 1 |
| Shimoda, S | 1 |
| Kajiwara, E | 1 |
| Hayashi, J | 1 |
| Fabrizi, F | 1 |
| Negro, F | 1 |
| Bondin, M | 1 |
| Cacoub, P | 1 |
| Örmeci, N | 1 |
| Sezgin, O | 1 |
| Karaali, R | 1 |
| Aygen, B | 1 |
| Turan, D | 1 |
| Yaras, S | 1 |
| Erdem, İ | 1 |
| Yildiz, O | 1 |
| Karakaya, F | 1 |
| Ateş, K | 1 |
| Asiller, ÖÖ | 1 |
| Said, M | 1 |
| Omar, H | 1 |
| Soliman, Z | 1 |
| Dabes, H | 1 |
| Hamed, S | 1 |
| Opdebeeck, B | 1 |
| Maudsley, S | 1 |
| Azmi, A | 1 |
| De Maré, A | 1 |
| De Leger, W | 1 |
| Meijers, B | 1 |
| Verhulst, A | 1 |
| Evenepoel, P | 1 |
| D'Haese, PC | 2 |
| Neven, E | 1 |
| Behets, GJ | 1 |
| Dams, G | 1 |
| Damment, SJ | 1 |
| De Broe, ME | 1 |
| Liapakis, A | 1 |
| Hassanein, T | 1 |
| Zamor, PJ | 1 |
| Zuckerman, E | 1 |
| Wan, S | 1 |
| Jackson, B | 1 |
| Alric, L | 1 |
| Bonnet, D | 1 |
| Kazes, I | 1 |
| Desmons, A | 1 |
| Fadel, F | 1 |
| Oudart, JB | 1 |
| Santos-Weiss, IC | 1 |
| Millart, H | 1 |
| Touré, F | 1 |
| Rieu, P | 1 |
| Maruyama, Y | 1 |
| Hachicha, M | 1 |
| Botta-Fridlund, D | 1 |
| Elbasha, E | 1 |
| Nwankwo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease[NCT02092350] | Phase 2/Phase 3 | 237 participants (Actual) | Interventional | 2014-03-17 | Completed | ||
| Pharmacokinetics of Low-dose Sofosbuvir in Dialysis-dependent Patients With Hepatitis C Virus Infection[NCT03883698] | Phase 3 | 30 participants (Actual) | Interventional | 2019-03-15 | Completed | ||
| Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?[NCT04719338] | 30 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| An Open-label, Phase I, One-dose, One-meal, Balance Study Comparing the Absorption of Dietary Phosphorus When Administering FOSRENOL® (Lanthanum Carbonate) or RENVELA® (Sevelamer Carbonate) in Healthy Adult Volunteers[NCT00875017] | Phase 1 | 31 participants (Actual) | Interventional | 2009-04-20 | Completed | ||
| Open-Labeled Trial Of Direct-Acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors[NCT02743897] | Phase 1/Phase 2 | 62 participants (Actual) | Interventional | 2016-05-01 | Completed | ||
| A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients: The MATCH-D Study[NCT03791814] | Phase 4 | 0 participants (Actual) | Interventional | 2019-01-01 | Withdrawn (stopped due to The study was stopped due to difficulty in identifying potential patients.) | ||
| "Real World Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring"[NCT03365635] | Phase 4 | 6 participants (Actual) | Interventional | 2019-09-22 | Completed | ||
| Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors[NCT03146741] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This analysis includes the Immediate Treatment + Intensive PK group and the placebo treatment period for the Deferred Treatment group. (NCT02092350)
Timeframe: Up to Week 12
| Intervention | Participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 0 |
| Deferred Treatment | 5 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This analysis includes the Immediate Treatment + Intensive PK group and the placebo treatment period for the Deferred Treatment group. (NCT02092350)
Timeframe: Up to Week 14
| Intervention | Participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 93 |
| Deferred Treatment | 96 |
SVR12 was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) lower than the limit of quantification (LLoQ) 12 weeks after completing study therapy. HCV RNA was measured using the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0®, which has a LLoQ of 15 IU/mL. (NCT02092350)
Timeframe: Week 24 (Immediate Treatment + Intensive PK) or Week 40 (Deferred Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 99.1 |
| Deferred Treatment | 98.0 |
SVR24 was defined as HCV RNA
Timeframe: Week 36 (Immediate Treatment + Intensive PK) or Week 52 (Deferred Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 97.4 |
| Deferred Treatment Group | 98.0 |
SVR4 was defined as HCV RNA
Timeframe: Week 16 (Immediate Treatment + Intensive PK) or Week 32 (Deferred Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 100.00 |
| Deferred Treatment Group | 99.0 |
Net Calcium Absorption (Lanthanum carbonate period) = Calcium ingested in meal minus (Rectal effluent calcium after Lanthanum carbonate + meal minus Rectal effluent calcium after fasting). Net Calcium Absorption (Sevelamer Carbonate period) = Calcium ingested in meal minus (Rectal effluent calcium after Sevelamer carbonate + meal minus Rectal effluent calcium after fasting). Net Calcium Absorption (Meal only period) = Calcium ingested in meal minus (Rectal effluent calcium after meal only minus Rectal effluent calcium after fasting). (NCT00875017)
Timeframe: 10 hours post-dose
| Intervention | mg (Least Squares Mean) |
|---|---|
| Lanthanum Carbonate | 49.46 |
| Sevelamer Carbonate | 70.13 |
| Meal Only | 65.02 |
Net phosphorous absorption (Lanthanum carbonate period) = phosphorous ingested in meal minus (Rectal effluent phosphorous after Lanthanum carbonate + meal minus Rectal effluent phosphorous after fasting). Net phosphorous absorption (Sevelamer Carbonate period) = Phosphorous ingested in meal minus (Rectal effluent phosphorous after Sevelamer carbonate + meal minus Rectal effluent phosphorous after fasting). Net phosphorous absorption (Meal only period) = Phosphorous ingested in meal minus (Rectal effluent phosphorous after meal only minus Rectal effluent phosphorous after fasting). (NCT00875017)
Timeframe: 10 hours post-dose
| Intervention | mg (Least Squares Mean) |
|---|---|
| Lanthanum Carbonate | 156.03 |
| Sevelamer Carbonate | 221.78 |
| Meal Only | 281.68 |
Net Phosphorous Binding (Lanthanum carbonate period) = Rectal effluent phosphorous after Lanthanum carbonate + meal minus Rectal effluent phosphorous after meal only. Net Phosphorous Binding (Sevelamer carbonate period) = Rectal effluent phosphorous after Sevelamer carbonate + meal minus Rectal effluent phosphorous after meal only. (NCT00875017)
Timeframe: 10 hours post-dose
| Intervention | mg (Least Squares Mean) |
|---|---|
| Lanthanum Carbonate | 135.05 |
| Sevelamer Carbonate | 63.15 |
Subjects with post-treatment sustained virologic response (SVR) = Number of subjects with negative HCV RNA 12 weeks after completing therapy / number of subjects treated post-kidney transplantation (NCT02743897)
Timeframe: Baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Direct-acting Antiviral Treatment for HCV | 62 |
Number of subjects with major adverse events attributable to HCV therapy in post-kidney transplant (NCT02743897)
Timeframe: Baseline to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Direct-acting Antiviral Treatment for HCV | 1 |
The number of participants for whom their third party insurance approved payment of the DAA (study drug) (NCT03365635)
Timeframe: Within one month of last patient enrolled
| Intervention | Participants (Count of Participants) |
|---|---|
| Genotype 1a -Rx Naive -no NS5A Polymorph | 0 |
| Genotype 1b - Rx Naive | 0 |
Absence of HCV by viral RNA quantitation at 12 weeks post treatment (NCT03365635)
Timeframe: 12 weeks after completion of Elbasivir/Grazoprevir treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Genotype 1a -Rx Naive -no NS5A Polymorph | 3 |
| Genotype 1a, Rx Naive + NS5A Polymorph | 0 |
| Genotype 1b - Rx Naive | 1 |
| Genotype 1a/1b -Prior INF or NS3/4A | 0 |
| Genotype4 - Treatment Naive | 0 |
The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR; negative HCV RNA after completing Zepatier therapy) / (number of subjects treated with Zepatier post-heart transplantation) (NCT03146741)
Timeframe: Baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Zepatier (Grazoprevir 100mg and Elbasvir 50 mg) | 9 |
(NCT03146741)
Timeframe: Baseline to 52 weeks
| Intervention | Severe adverse event (Number) |
|---|---|
| Zepatier (Grazoprevir 100mg and Elbasvir 50 mg) | 0 |
2 reviews available for carbamates and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofur | 2018 |
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Combinations; Dr | 2016 |
3 trials available for carbamates and Renal Insufficiency, Chronic
27 other studies available for carbamates and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
Topics: Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis | 2023 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Ther | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Comor | 2020 |
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Ther | 2020 |
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Thera | 2020 |
Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolid | 2020 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropa | 2022 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates | 2020 |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combi | 2022 |
Quantification of carbamylated albumin in serum based on capillary electrophoresis.
Topics: Adult; Aged; Carbamates; Diabetic Nephropathies; Electrophoresis, Capillary; Female; Humans; Male; M | 2017 |
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
Topics: Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; | 2017 |
Carbamylation is a competitor of glycation for protein modification in vivo.
Topics: Albumins; Animals; Blood Glucose; Blood Proteins; Carbamates; Cyanates; Diabetes Mellitus, Experimen | 2018 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug | 2018 |
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Topics: Adult; Antiviral Agents; Carbamates; Comorbidity; Dose-Response Relationship, Drug; Drug Monitoring; | 2019 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combinat | 2018 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Ma | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Fe | 2019 |
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cohort Studies; C | 2018 |
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropan | 2019 |
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt | 2019 |
Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance.
Topics: Animals; Biological Products; Biopsy, Needle; Carbamates; Disease Models, Animal; Glucose Intoleranc | 2019 |
Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD.
Topics: Animals; Carbamates; Collagen; Disease Models, Animal; Extracellular Matrix; Female; Kinetics; Mice; | 2013 |
Homocitrulline as marker of protein carbamylation in hemodialyzed patients.
Topics: Biomarkers; Carbamates; Citrulline; Hemoglobin A; Humans; Longitudinal Studies; Renal Dialysis; Rena | 2016 |
Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; | 2017 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Hum | 2016 |
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclo | 2017 |